Dogwood Therapeutics, Inc. (DWTX)
DWTX moved a median of -0.21% 30 minutes after news, and -0.67% by the close. How DWTX actually reacts to news — the realized, point-in-time move the market made, measured across 110 labeled events over the last three years with zero look-ahead.
DWTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 33% | 82 |
| 30-min | -0.21% | 40% | 105 |
| 60-min | -0.10% | 36% | 108 |
| to close | -0.67% | 38% | 110 |
| Middle 50% of DWTX reactions | -1.34% to +1.20% |
|---|---|
| Median reaction (30-min) | -0.21% |
| Measured reactions | 110 |
Half of all Dogwood Therapeutics, Inc. news events land between -1.34% and +1.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DWTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DWTX's baseline. Nothing else.
Recent DWTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. | Press release | GlobeNewswire | -9.29% | — | |
| Form 8-K Dogwood Therapeutics, For: Oct 19 | SEC filing · Form 8-K | SEC EDGAR | -9.29% | — | |
| Dogwood to Participate in the 2026 Maxim Growth Summit | Press release | GlobeNewswire | +0.00% | -3.19% | |
| Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial | Press release | GlobeNewswire | -0.34% | -4.90% | |
| Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 | Press release | GlobeNewswire | -0.93% | -4.19% | |
| Form 10-Q Dogwood Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.50% | +8.04% | |
| Dogwood Therapeutics Announces Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.00% | +3.13% | |
| Form 8-K Dogwood Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.13% | |
| Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 | Press release | GlobeNewswire | +1.48% | +2.22% | |
| Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board | Press release | GlobeNewswire | — | -9.04% | |
| Form 8-K Dogwood Therapeutics, For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.03% | |
| Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | Press release | GlobeNewswire | -4.06% | -13.71% | |
| Form 10-Q Dogwood Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -5.18% | |
| Dogwood Therapeutics Announces First Quarter 2026 Financial Results | Press release | GlobeNewswire | +2.23% | +10.62% | |
| Form 8-K Dogwood Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +2.23% | +10.62% | |
| Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 | Press release | GlobeNewswire | -0.30% | -4.88% | |
| Form ARS Dogwood Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -0.73% | |
| Form DEF 14A Dogwood Therapeutics, For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | — | -5.63% | |
| Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M | Press release | GlobeNewswire | -0.68% | -4.76% | |
| Form PRE 14A Dogwood Therapeutics, For: Jun 16 | SEC filing · Form PRE | SEC EDGAR | +1.24% | -0.62% | |
| Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy | Press release | GlobeNewswire | -2.33% | -0.58% | |
| Form 8-K Dogwood Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.77% | |
| Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +4.36% | -4.19% | |
| Form 10-K Dogwood Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.03% | -6.38% | |
| Form 8-K Dogwood Therapeutics, For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +4.36% | -4.19% | |
| Form 8-K Dogwood Therapeutics, For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | — | +1.66% | |
| Form DEF 14A Dogwood Therapeutics, For: Mar 11 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -2.91% | |
| Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 | Press release | GlobeNewswire | +0.00% | +1.38% | |
| Form EFFECT Dogwood Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | -3.46% | |
| Form PRE 14A Dogwood Therapeutics, For: Mar 11 | SEC filing · Form PRE | SEC EDGAR | -2.69% | +4.75% | |
| Form 8-K Dogwood Therapeutics, For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -1.44% | |
| Form S-3 Dogwood Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +2.21% | |
| Form 8-K Dogwood Therapeutics, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -1.09% | -3.26% | |
| Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development | Press release | GlobeNewswire | +2.81% | +5.25% | |
| Form S-8 Dogwood Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.62% | -10.66% | |
| Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain | Press release | GlobeNewswire | -4.69% | -24.38% | |
| Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 | Press release | ACCESS Newswire | — | -2.20% | |
| Form 8-K Dogwood Therapeutics, For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Form 8-K Dogwood Therapeutics, For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | — | +0.80% | |
| Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 | Press release | ACCESS Newswire | -1.78% | +0.54% | |
| Form 10-Q Dogwood Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.15% | |
| Dogwood Therapeutics Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.55% | -5.46% | |
| Form 8-K Dogwood Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | -5.46% | |
| Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 | Press release | ACCESS Newswire | -1.46% | +7.61% | |
| Form DEF 14A Dogwood Therapeutics, For: Nov 21 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -8.16% | |
| Form S-3/A Dogwood Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.67% | -3.19% | |
| Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 | Press release | ACCESS Newswire | -5.99% | +0.97% | |
| Form 8-K Dogwood Therapeutics, For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | +3.68% | -1.10% | |
| Form DEFA14A Dogwood Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +3.68% | -1.10% | |
| Form PRE 14A Dogwood Therapeutics, For: Nov 21 | SEC filing · Form PRE | SEC EDGAR | -2.39% | -10.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DWTX section they belong to.
Where else DWTX is measured.
DWTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Dogwood Therapeutics, Inc.'s median reaction calculated?
Every labeled DWTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 110 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of DWTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DWTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.